Radiopharmaceutical therapy has been widely adopted owing primarily to the
development of novel radiopharmaceuticals. To fully utilize the potential of
these RPTs in the era of precision medicine, therapy must be optimized ...
INTRODUCTION: Nuclear medicine infection imaging is routinely performed with the
use of leukocytes radiolabelled with technetium-99m hexamethylpropyleneamine
oxime ([99mTc]Tc-HMPAO) and single-photon emission computed ...
Pascual, Thomas N.B.; Paez, Diana; Iagaru, Andrei; Gnanasegaran, Gopi; Lee, Sze Ting; Sathekge, Mike Machaba; Buatti, John M.; Giammarile, Francesco; Al-Ibraheem, Akram; Pardo, Manuela Arevalo; Baum, Richard P.; De Bari, Berardino; Ben-Haim, Simona; Blay, Jean-Yves; Brink, Anita; Estrada-Lobato, Enrique; Fanti, Stefano; Golubic, Anja Tea; Hatazawa, Jun; Israel, Ora; Kiess, Ana; Knoll, Peter; Louw, Lizette; Mariani, Giuliano; Mirzaei, Siroos; Orellana, Pilar; Prior, John O.; Urbain, Jean-Luc; Vichare, Shrikant; Vinjamuri, Sobhan; Virgolini, Irene; Scott, Andrew M.(Springer, 2024-07)
PURPOSE :
The recent development and approval of new diagnostic imaging and therapy approaches in the field of theranostics have revolutionised nuclear medicine practice. To ensure the provision of these new imaging and ...
Kleynhans, Janke; Ebenhan, Thomas; Cleeren, Frederik; Sathekge, Mike Machaba(Springer, 2024-06)
Preclinical studies are essential for effectively evaluating TAT radiopharmaceuticals. Given the current suboptimal supply chain of these radionuclides, animal studies must be refined to produce the most translatable TAT ...
BACKGROUND :
[18F]FDG-PET/CT is a sensitive non-invasive tool for assessing treatment response in patients with pulmonary tuberculosis. The data on the performance of [18F]FDG-PET/CT for response assessment among patients ...
Mdanda, Sipho; Ngema, Lindokuhle M.; Mdlophane, Amanda; Sathekge, Mike Machaba; Zeevaart, Jan Rijn(MDPI, 2023-06-13)
The actinium-225 (225Ac) radioisotope exhibits highly attractive nuclear properties for
application in radionuclide therapy. However, the 225Ac radionuclide presents multiple daughter
nuclides in its decay chain, which ...
Despite recent advances in multimodality therapy for glioblastoma (GB) incorporating
surgery, radiotherapy, chemotherapy and targeted therapy, the overall prognosis remains poor. One
of the interesting targets for GB ...
Vorster, Mariza; Sathekge, Mike Machaba(Elsevier, 2024-07)
Alpha theranostics offer an attractive alternative form of therapy, which has best been investigated and documented with 225Ac-PSMA in patients with prostate cancer. Advantages offered by targeted alpha therapy include ...
Patients with cancer are presumed to be vulnerable to an increased risk of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe clinical outcomes due to
the immunocompromised state mediated ...
Du Plessis, Tamarisk; Ramkilawon, Gopika; Duncombe Rae, William Ian; Botha, Tanita; Martinson, Neil A.; Dixon, S.A.P.; Kyme, Andre; Sathekge, Mike Machaba(Springer, 2023-09)
PURPOSE: Accurate segmentation (separating diseased portions of the lung from normal appearing lung) is a challenge in radiomic studies of non-neoplastic diseases, such as pulmonary tuberculosis (PTB). In this study, we ...
AIM : The integration of innovative radio-pharmaceutical agents targeting prostate-specific membrane antigen (PSMA) within nuclear medicine has transformed prostate cancer detection and management. This study aims to ...
Vorster, M.; Hadebe, B.P.; Sathekge, Mike Machaba(Frontiers Media, 2023-08-04)
INTRODUCTION : Breast cancer is a complex disease and constitutes the leading
cause of cancer in women globally. Conventional treatment modalities include
surgery, chemotherapy, radiation therapy, and hormonal therapy; ...
PURPOSE : 225Ac-PSMA-617 has demonstrated good anti-tumor effect as a treatment option for metastatic castration-resistant
prostate cancer (mCRPC) patients. No study has previously assessed treatment outcome and survival ...